GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Net Margin %

CSL (CMXHF) Net Margin % : 24.36% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CSL Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. CSL's Net Income for the six months ended in Dec. 2023 was $1,901 Mil. CSL's Revenue for the six months ended in Dec. 2023 was $7,804 Mil. Therefore, CSL's net margin for the quarter that ended in Dec. 2023 was 24.36%.

The historical rank and industry rank for CSL's Net Margin % or its related term are showing as below:

CMXHF' s Net Margin % Range Over the Past 10 Years
Min: 16.65   Med: 22.67   Max: 25.26
Current: 17.62


CMXHF's Net Margin % is ranked better than
87.95% of 1029 companies
in the Biotechnology industry
Industry Median: -157.22 vs CMXHF: 17.62

CSL Net Margin % Historical Data

The historical data trend for CSL's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Net Margin % Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.55 23.10 23.14 21.49 16.65

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.31 10.55 23.38 9.16 24.36

Competitive Comparison of CSL's Net Margin %

For the Biotechnology subindustry, CSL's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Net Margin % distribution charts can be found below:

* The bar in red indicates where CSL's Net Margin % falls into.



CSL Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

CSL's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin=Net Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=2194/13174
=16.65 %

CSL's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1901/7804
=24.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL  (OTCPK:CMXHF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


CSL Net Margin % Related Terms

Thank you for viewing the detailed overview of CSL's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (CMXHF) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.